Medtronic (NYSE:MDT) announced today the FDA approved its Intellis and Vanta neurostimulator for treating chronic pain. The approval covers the Intellis rechargeable neurostimulator and the Vanta recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy. The new indication offers DPN patients access to Medtronic’s spinal cord stimulation (SCS) portfolio of both […]
Pain Management
FDA approves expanded labeling for Nevro spinal cord stimulation
Nevro (NYSE:NVRO) today said it received FDA approval for expanded labeling of its Senza spinal cord stimulations system to treat non-surgical refractory back pain (NSRBP). Redwood City, California–based Nevro designed the 10 kHz therapy to improve pain relief and reduce opioid use. The 12-month results from a study of the system showed that patients who […]
NIH launches $9.8M neuromodulation competition
The National Institutes of Health (NIH) announced today that it launched the first phase of its Neuromod Prize competition. Neuromod Prize, a $9.8 million competition, aims to accelerate the development of neuromodulation therapies. NIH seeks scientists, engineers and clinicians to submit novel concepts and clinical development plans to demonstrate solutions for stimulating the peripheral nervous […]
NeuroMetrix’s Quell wins FDA breakthrough designation to treat certain chemo side effects
NeuroMetrix (NSDQ:NURO) announced today that it received FDA breakthrough device designation for its Quell technology. Woburn, Massachusetts-based NeuroMetrix’s Quell garnered the breakthrough nod for reducing moderate-to-severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that have persisted for at least six months following the end of chemotherapy. Shares of NURO were up 36.6% at $6.72 per share […]
Medtronic touts study of DTM spinal cord stimulation for pain relief
Medtronic (NYSE:MDT) announced today that three-month data shows meaningful pain relief using its DTM spinal cord stimulation (SCS) therapy. The on-label, prospective, multi-center study showed meaningful relief using DTM SCS endurance therapy, a modified, lower-energy variation of Medtronic’s Differential Target Multiplexed (DTM) SCS therapy for chronic overall, back or leg pain. According to a news […]
Stratus Medical picks up trio of patents for its pain-treating ablation technology
Stratus Medical announced today that it received three new patents for its radiofrequency (RF) ablation treatment for chronic pain. Magnolia, Texas-based Stratus said in a news release that the patents, which issued in the U.S., Brazil and India, highlight the growth of its intellectual property portfolio for its highly differentiated ablation technology. The patents include […]
UnitedHealthcare to cover Nevro’s spinal cord stimulation treatment for chronic pain
Nevro (NYSE:NVRO) announced today that UnitedHealthcare will provide coverage for its painful diabetic neuropathy (PDN) treatment. Redwood City, California–based Nevro’s Senza 10 kHz spinal cord stimulation (SCS) therapy will now be covered by the largest private health insurance company in the U.S. for dates of service on or after March 1, 2022, according to a […]
Relievant Medsystems’ Intracept receives new CPT codes to aid reimbursement efforts
Relievant Medsystems announced today that two new Category I Current Procedural Terminology (CPT) codes are now in effect for Intracept. Minneapolis-based Relievant designed its Intracept device and procedure to treat chronic low back pain (CLBP) from degenerative disc disease with Modic changes. It involves a minimally invasive procedure that targets the basivertebral nerve with radiofrequency-based […]
Avanos Medical to buy OrthogenRx for $160M
Avanos Medical today announced it entered into a definitive agreement to acquire OrthogenRx for $160 million. OrthogenRx makes viscosupplementation therapies to treat knee osteoarthritis pain, as well as commercial hyaluronic acid (HA) therapy products GenVisc 850 and TriVisc. Avanos will purchase the company for $130 million in cash at closing and an additional $30 million […]
Virpax reports positive non-human study results for topical spray film that treats chronic pain
Virpax Pharmaceuticals (NSDQ:VRPX) today reported positive results from a study of its Epoladerm treatment for chronic pain management. Berwyn, Pennsylvania-based Virpax designed Epoladerm, one of its lead investigational products, for managing pain associated with osteoarthritis of the knee. Get the full story at our sister site, Drug Delivery Business News.
FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump
Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy. Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group. Get the full story at our sister site, Drug Delivery Business News.